Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 2/20 | 0.54 |
| ▸ | SRC | P12931 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 4/20 | 0.48 |
| ▸ | CES1 | P23141 | 4/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4799828 | 0.98 | EGFR (1.00) | EGFRALDH1A1MAPTLMNAUSP2 | |
| SCHEMBL15245115 | 0.90 | EGFR (0.81) | EGFRALDH1A1MAPTLMNAUSP2 | |
| SCHEMBL11800908 | 0.89 | EGFR (0.79) | EGFRALDH1A1MAPTLMNAUSP2 | |
| SCHEMBL6222039 | 0.81 | EGFR (0.69) | EGFRALDH1A1MAPTLMNAHTT | |
| SCHEMBL11799603 | 0.81 | EGFR (0.69) | EGFRALDH1A1MAPTLMNAUSP2 | |
| SCHEMBL11019161 | 0.81 | EGFR (0.69) | EGFRMAPTABL1SRCSMN1; SMN2 | |
| SCHEMBL6223672 | 0.81 | EGFR (0.69) | EGFRABL1SRCCES2CES1 | |
| Hydrochloric Acid SCHEMBL4803436 | 0.80 | EGFR (0.70) | EGFRALDH1A1MAPTLMNAHTT | |
| Hydrochloric Acid SCHEMBL4810682 | 0.80 | EGFR (0.70) | EGFRABL1SRCCES2CES1 | |
| Hydrochloric Acid SCHEMBL4805251 | 0.80 | EGFR (0.70) | EGFRALDH1A1MAPTABL1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0156785-A1 | 2-(Aminoalkyl)-acrylophenones, their preparation and their use | S.A.R.L. GALEPHAR (FR) | 1985-10-02 | — | — | EP | claimed |
| EP-2819662-B1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2019-04-10 | — | — | EP | disclosed |
| US-9552457-B2 | Reprogramming effector protein interactions to correct epigenetic defects in cancer | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2017-01-24 | — | — | US | disclosed |
| US-9552457-B2 | Reprogramming effector protein interactions to correct epigenetic defects in cancer | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2017-01-24 | — | — | US | disclosed |
| US-20150154345-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2015-06-04 | — | — | US | disclosed |
| US-20150154345-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2015-06-04 | — | — | US | disclosed |
| WO-2013127011-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2013-09-06 | — | — | WO | disclosed |
| US-5169958-A | Reacting, 3-amino-2-propen-1-ones with magnesium halide in solvent | BASF AKTIENGESELLSCHAFT (DE) | 1992-12-08 | — | — | US | disclosed |
| EP-0480242-A2 | Method for the production of alpha,beta-unsaturated carbonyl compounds | BASF Aktiengesellschaft (DE) | 1992-04-15 | — | — | EP | disclosed |
| EP-0073456-B1 | TETRAAZAANNULENE COBALT COMPLEX COMPOUNDS AND METHOD FOR PREPARATION THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1985-11-27 | — | — | EP | disclosed |
| EP-0156785-A1 | 2-(Aminoalkyl)-acrylophenones, their preparation and their use | S.A.R.L. GALEPHAR (FR) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150154345-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | CBX2, BPTF, CBX4 | EGFR 2572/4885ALDH1A1 4214/4885MAPT 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.